X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Biotechnology

Healthcare
$2.98 +1.49%

+$0.06 today

Market cap
$304.30M
Beta
0.37
P/E (TTM)
-5.2
EPS (TTM)
-$0.79
52W Low $1.35High $4.83

Volume 0.64M

Average 0.40M

XFOR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

X4 Pharmaceuticals, Inc.NASDAQ: XFOR

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 77.9%

Gross margin was 77.9% in Q1 FY2026, down 4.7 pp from a year earlier. On a trailing-twelve-month basis it was 79.4%, down 1.2 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
77.9%-7.0 pp QoQ
Last fiscal yearDec 2025
82.2%+13.3 pp YoY
LTMMar 2026
79.4%-1.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-4.7 pp——
1 year+13.3 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
82.2%
Year-over-year change
+13.3pp

Gross Margin vs competitors

How XFOR compares with its peers on the latest reported figures

  • XFOR's LTM Mar 2026 gross margin of 79.4% is the lowest of the 3 companies compared; the peer median is 98.0%.
  • Its year-over-year change of -1.2 pp is the lowest of 3, against a peer median of -0.1 pp.
XFOR Competitors Peer median
Gross Margin for XFOR and competitors
Company Period LTM level YoY 3-year change
INMBINmune Bio, Inc.FY2025100.0% +0.0 pp+0.0 pp
KPTIKaryopharm Therapeutics Inc.LTM Mar 202696.0% -0.1 pp-0.8 pp
XFORX4 Pharmaceuticals, Inc.LTM Mar 202679.4% -1.2 pp—
OKUROnKure Therapeutics, Inc.FY2025— ——
Peer median (excluding XFOR) 98.0%-0.1 pp-0.4 pp

Competitors are the stored peer set for XFOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0002.56M35.11M
Cost of Revenue1.89M00797K6.26M
Gross Profit(1.89M)001.76M28.86M
Gross Margin———68.8%82.2%
Research & Development48.76M61.06M72.02M81.64M72.22M
Selling, General & Admin24.7M27.02M35.51M61.52M43.52M
Operating Expenses73.46M87.57M107.52M38.16M115.74M
Depreciation & Amortization1.89M513K419K796K1.28M
EBITDA(83.15M)(89.33M)(94.89M)(27.58M)(69.01M)
EBITDA Margin———-1078.5%-196.5%
Operating Income(75.35M)(87.57M)(107.52M)(36.4M)(86.88M)
Operating Margin———-1423.6%-247.4%
Interest Income10K219K4.58M5.77M4.58M
Interest Expense3.64M3.99M5.78M8.77M8.88M
Other Income / Expenses(13.33M)(6.27M)6.43M(739K)7.73M
Income Before Tax(88.68M)(93.84M)(101.09M)(37.14M)(79.16M)
Pre-Tax Margin———-1452.5%-225.4%
Income Tax Expense17K28K78K310K41K
Net Income(88.7M)(93.87M)(101.17M)(37.45M)(79.2M)
Net Margin———-1464.6%-225.6%
EPS (Basic)(119.58)(45.60)(17.07)(5.59)(1.87)
EPS (Diluted)(119.58)(45.60)(17.07)(5.59)(1.87)
Weighted Avg Shares858.3K2.12M5.93M6.7M42.29M
Weighted Avg Shares (Diluted)858.3K2.12M5.93M6.7M42.29M

X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.